Osteoporosis

CTAF

Osteoporosis, the weakening of the bones through loss of bone mineral content and a decrease in bone quality, is a common disease of aging that affects approximately 10 million Americans. Approximately half of women and one quarter of men will suffer at least one fracture due to osteoporosis during their lifetimes. Experts estimate that there are approximately two million osteoporotic fractures each year, which results in $19 billion in related costs.3 By 2025, these figures are predicted to grow to approximately three million fractures and $25 billion in costs annually as the population of older Americans increases.

Interventions of Interest:

  • Abaloparatide (Radius Health, Inc.)
  • Romosozumab (Amgen, Inc. and UCB, Inc.)
  • Teriparatide (Forteo®, Eli Lilly and Co.)

Associated Meetings

June 30, 2017

Location TBD (California)

The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.


Key Dates

Associated Materials

11/11/2016 – 12/01/2016

The open input period is now closed.


12/05/2016

The draft scoping document was open to public comment until December 23, 2016.


12/05/2016

12/05/2016 – 12/23/2016

01/09/2017

04/28/2017
Draft Evidence Report

04/28/2017
Draft Voting Questions

04/28/2017 – 05/25/2017
Public Comments

06/16/2017
Evidence Report

06/16/2017
Revised Voting Questions

06/16/2017
Response to Comments

06/30/2017
Meeting Agenda

07/14/2017
Final Evidence Report and Meeting Summary